share_log

What Analysts Are Saying About Vertex Pharmaceuticals Stock

What Analysts Are Saying About Vertex Pharmaceuticals Stock

分析師對福泰製藥股票的看法
Benzinga ·  10/01 08:01
15 analysts have expressed a variety of opinions on Vertex Pharmaceuticals (NASDAQ:VRTX) over the past quarter, offering a diverse set of opinions from bullish to bearish.
在過去的一個季度中,有15名分析師對福泰製藥(納斯達克:VRTX)發表了各種觀點,提供了從看好到看淡的多樣化觀點。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表提供了他們最近的評級快照,展示了情緒在過去30天中的演變情況,並將其與之前的月份進行比較。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $500.53, a high estimate of $600.00, and a low estimate of $376.00. Witnessing a positive shift, the current average has risen by 8.29% from the previous average price target of $462.20.
分析師評估的12個月價格目標揭示了更多見解,平均目標爲500.53美元,高估爲600.00美元,低估爲376.00美元。目前的平均目標已經出現正面變化,比上一次的平均價格目標462.20美元上漲了8.29%。
Breaking Down Analyst Ratings: A Detailed Examination...
分析師評級分析...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論